{
  "id": 461707,
  "title": "AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile",
  "url": "https://urgent.news/2026/08/10/abcellera-announces-positive-top-line-phase-2-clinical-trial-results",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-10T11:06:48.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/abcellera-announces-positive-top-line-phase-2-clinical-trial-results-for-abcl635-demonstrating-significant-reduction-in-frequency-and-severity-of-vasomotor-symptoms-and-a-favorable-tolerability-profi"
  },
  "original_language": "en",
  "account": null,
  "summary": "AbCellera, a company listed on the Nasdaq under the ticker ABCL, has reported positive top-line results from the Phase 2 clinical trial of ABCL635, an investigational neurokinin 3 receptor (NK3R) antagonist antibody. This antibody is being developed as a non-hormonal, long-acting, subcutaneous treatment for moderate-to-severe vasomotor symptoms (VMS M-S), commonly known as hot flashes, experienced by menopausal women. The trial met its primary efficacy endpoints by demonstrating statistically significant reductions in both the frequency and severity of VMS M-S at week 4, compared to the placebo group, following a single dose. Additionally, ABCL635 was observed to significantly improve sleep quality and overall patient perception of improvement, as measured by the patient global impression of change (PGI-C).",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Endpoints News",
        "title": "AbCellera details 'striking' Phase 2 data for vasomotor symptoms treatment",
        "url": "https://urgent.news/2026/08/10/abcellera-details-striking-phase-2-data-for-vasomotor-symptoms",
        "published": "2026-08-10T15:33:49.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}